RESEARCH SUMMARY

My research is patient oriented and involves primarily various aspects of Parkinson's disease including: markers of disease progression, pathophysiology of motor fluctuations, and autonomic failure in Parkinson's disease. The Division of Movement Disorders is actively involved with clinical trials in neuroprotection in Parkinson's disease and treatments of spasticity and dystonia.

SELECTED PUBLICATIONS

Refereed articles:

Carson RP, Appalsamy M, Diedrich A, Davis TL, and Robertson D. Animal model of neuropathic tachycardia syndrome. Hypertension 37:1357-1361, 2001.

Jorga KM, Davis TL, Kurth MC, Saint-Hilaire MH, LeWitt PA, Fotteler B, Zurcher G, Rabbia M. Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism. Clin Neuropharmacol 23:98-105, 2000.

Scott WK, Yamaoka LH, Stajich JM, Scott BL, Watts R, Nance M,Hubble J, Koller W, Stern M, Colcher A, Allen FH, Hiner BC, Jankovic J, Ondo W, Laing NG, Mastaglia F, Goetz C, paapert E, Small GW, Masterman D, Haines JL, Davis TL, Vance JM, Roses AD, Pericak-Vance MA. The alpha-synuclein gene is not a major risk factor in familial Parkinson’s disease. Neurogenetics 2:191-192, 1999.

Davis TL, Charles PD, Esper G. A definition of “on”: relationships between patient diaries and the Unified Parkinson’s Disease Rating Scale (UPDRS). Parkinsonism and Related Disorders 5:99-101, 1999.

Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharma 18: 333-337, 1995.

Davis TL, Roznoski M, Burns RS. Effects of tolcapone in Parkinson’s disease patients on L-Dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 10: 349-351, 1995.

Book chapters and invited reviews:

Estrada J, Biaggioni I, Davis TL, Mosqueda-Garcia R, Robertson RM, Robertson D. Multiple Systems Atrophy: Coping with the Shy-Drager syndrome. (In preparation).

Damian MM, Davis TL, Konrad PE, Roberts AG, Pfister AA, Charles PD. Deep brain stimulation: A new treatment for Parkinson’s disease. Tennessee Medicine 96(1): 33-35, 2003.

Davis TL. Catechol-O-methyltransferase inhibitors in Parkinson’s disease: guidelines for effective use. In: Palmer KJ (ed.). Drug Treatment Issues in Parkinson’s Disease. (Adis International, Philadelphia, PA). pp. 4-48, 2000.

Robertson D, Davis TL. Neurological and Related Causes of Syncope: The Importance of Recognition and Treatment. In: Grubb BP, Olshansky B (eds.). Syncope: Mechanisms and Management. (Futura Publishing Company, Armonk, NY).

Davis TL. Parkinson’s Disease. In: Robertson D, Low PA, Polinski RJ (eds.). Primer on Autonomic the Autonomic Nervous System (Academic Press, San Diego) pp. 219-221, 1996.

     
 
     

Faculty>
Thomas L. Davis. M.D., Associate Professor of Neurology

BIOGRAPHICAL SKETCH

Dr. Davis received his Bachelor’s degree from the College of Wooster, Wooster, Ohio, in 1981 and his M.D. from the University of Mississippi School of Medicine, Jackson, Miss., in 1985. He stayed in Jackson for a year of internship, then came to Vanderbilt’s Neurology department for his residency (1986-89). Davis left Vanderbilt for a two-year post-doctoral fellowship in Neuropharmacology at the National Institute of Neurological Disease and Stroke in Bethesda, Maryland. He returned to Vanderbilt to join the faculty in the Department of Neurology in 1991.

Davis has been the recipient of a number of honors, including being named Phi Beta Kappa in 1981, receiving the Sandoz Award in 1989, and being named to the list of Best Doctors in America: Midwest Region in 1996.

In addition to maintaining his clinical research activities and teaching responsibilities, he is currently director of the Division of Movement Disorders, director of the General Clinical Research Center (GCRC) Core Laboratory,an attending physician at Vanderbilt University Medical Center, a staff neurologist at the Nashville Veterans Administration Hospital, and neurological consultant at Vanderbilt-Stallworth Rehabilitation Hospital and Nashville General Hospital.

Davis is a member of the American Academy of Neurology, the American Autonomic Society, The Movement Disorder Society, and the American Society of Experimental Neurotherapeutics.


Printer friendly format

 

 

 

      
   
   
Vanderbilt University is committed to principles of equal opportunity and affirmative action.